MoonLake's Sonelokimab Shows Groundbreaking Results in Axial Spondyloarthritis Trial

MoonLake Immunotherapeutics has released topline results from its S-OLARIS Phase 2 trial of sonelokimab (SLK) in patients with axial spondyloarthritis (axSpA). The findings show strong efficacy and a consistent safety profile, with no new concerns identified during the study.

Experts have highlighted the drug's potential to fill a critical gap in treatment for this chronic inflammatory condition.

The S-OLARIS trial assessed SLK, an IL-17A and F Nanobody, in patients with axSpA. By Week 12, 81% of those treated achieved an ASAS40 response, a key measure of disease improvement. Over 80% also reached a 'clinically important improvement' based on the ASDAS-CRP score.

Imaging results reinforced these findings. SPARCC MRI scans revealed reduced inflammation and injury in the sacroiliac joint. PET imaging further confirmed a drop in inflammation and osteoblast activity, indicating the drug's impact on disease progression.

Objective biomarker analyses showed SLK's rapid and lasting effects in blocking immune pathways linked to inflammation and ossification. The safety data matched earlier trials, with no unexpected risks emerging.

Prof. Xenofon Baraliakos, Head of Rheumatology at the Rheumazentrum Ruhrgebiet Herne and EULAR President, emphasised SLK's potential to address unmet needs in axSpA. Prof. Kristian Reich, MoonLake's Founder and Chief Scientific Officer, called the results a critical step toward an effective treatment for patients.

This marks the fifth indication where SLK has shown positive data in Phase 2 and Phase 3 trials, broadening its potential use across inflammatory diseases.

The S-OLARIS trial results position SLK as a promising option for axSpA patients. Its ability to reduce inflammation, improve clinical scores, and maintain a stable safety profile suggests it could become a key therapy.

Further studies will determine its long-term role alongside existing treatments like NSAIDs, TNF inhibitors, and IL-blockers.